Loading company…
NeurAxis develops neuromodulation therapies for chronic conditions, with a focus on pediatric and adolescent patients.
Founded in 2011 in the US, NeurAxis develops and commercializes neuromodulation therapies for chronic conditions. Its IB-Stim device uses Percutaneous Electrical Nerve Field Stimulation (PENFS) to treat functional abdominal pain associated with disorders of gut-brain interaction in patients aged 8 to 21 years. The device is FDA cleared, drug-free and non-surgical. In 2021, the company raised venture funding from Catalytic Impact Foundation.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in